Clinical trials: Risk Factors
Carotid Intima- Media Thickness
A Study to Derive Normative Distribution of CIMT and to Determine Its Correlation With Cardiovascular Risk Factors
This non-interventional, prospective, multi-centric, cross-sectional study is aimed to obtain the distribution of measurements of CIMT in Indian subjects and will involve approx. 30 investigative sites from all over the country.
- Trial name
- Score-India (NCT01551875)
- Where
- 24 sites in India
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Adults, Not Healthy Adults
Survey of Incidence of Respiratory Tract Infections
The purpose of this study is to acquire reliable and current data on the actual incidence (post-COVID) of respiratory tract infections in the general adult population in the absence of any intervention.
- Trial name
- SIRTI (NCT06649032)
- Testing
- No intervention
- Where
- 23 sites in Italy
- Volunteers
- 1,736 people, healthy volunteers welcome
- Sponsor
- Lallemand Pharma AG
COVID-19
CORONA Germany- Clinical Outcome and Risk in Hospitalized COVID-19 Patients - An Epidemiological Study From Germany
This is a multicenter, observational, prospective, epidemiological cohort study at 45 hospitals in Germany, all part of a German hospital network. All hospitalized patients tested positive for SARS-CoV-2 will be included.
- Trial name
- CORONA Germany (NCT04659187)
- Where
- 8 sites in Germany
- Volunteers
- 4,000 people
- Sponsor
- Asklepios proresearch
Cardiovascular Disease, High Cardiovascular Risk
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.
- Conditions
- Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight
- Trial name
- CAMELLIA-TIMI (NCT02019264)
- Testing
- Lorcaserin hydrochloride
- Where
- 499 sites in United States, Australia and 6 more
- Volunteers
- 14,673 people
- Sponsor
- Eisai Inc.
Arthritis, Rheumatoid, Lung Diseases, Interstitial
Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors
The overall aim of the study is to develop and validate a Rheumatoid Arthritis-Interstitial Lung Disease (RA-ILD) clinical prediction model (screening tool) based on risk factors to guide screening for ILD in patients with RA…
- Trial name
- NCT05855109
- Where
- 28 sites in United States, France and 4 more
- Volunteers
- 1,304 people
- Sponsor
- Boehringer Ingelheim
Cardiovascular Risk
Level of Concordance Between Patients Perception and Physicians Evaluation of Cardiovascular Risk
This is a national, non interventional, prospective study performed in the general practice setting. The study has been designed : to assess the level of concordance between patients' cardiovascular risk perception and the…
- Trial name
- PERCEPTION (NCT01781416)
- Where
- France
- Volunteers
- 799 people
- Sponsor
- AstraZeneca
COVID-19
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing acute respiratory failure in patients aged ≥65 and patients aged ≥18 with…
- Trial name
- Mir-Age (NCT04393038)
- Testing
- ABX464
- Where
- 30 sites in Belgium, Brazil and 6 more
- Volunteers
- 509 people
- Sponsor
- Abivax S.A.
Hypercholesterolemia
Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)
The overall objective is to evaluate the efficacy and safety of ezetimibe (SCH 058235/MK-0653) 10 mg administered daily in conjunction with atorvastatin in participants with Heterozygous Familial Hypercholesterolemia (HeFH) or in…
- Trial name
- NCT03867318
- Testing
- Atorvastatin, Ezetimibe
- Volunteers
- 621 people
- Sponsor
- Organon and Co
Chronic Kidney Disease (CKD)
Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in Chronic Kidney Disease Stage 5 on Dialysis
The purpose of this study is to evaluate which clinical and laboratory factors are associated with major adverse cardiovascular event (MACE) in chronic kidney disease (CKD) patients on dialysis.
- Trial name
- NCT04042350
- Testing
- Non-interventional
- Where
- Sweden
- Volunteers
- 2,773 people
- Sponsor
- Astellas Pharma Europe Ltd.
Hypertension, Cardiovascular Diseases
Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients
The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risks.
- Trial name
- NCT00904371
- Where
- 36 sites in Slovenia
- Volunteers
- 211 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Cardiovascular Diseases
CANVAS - CANagliflozin cardioVascular Assessment Study
The study will assess canagliflozin (JNJ-28431754) in the treatment of patients with type 2 diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac events (MACE).
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases, Risk Factors
- Trial name
- CANVAS (NCT01032629)
- Testing
- Canagliflozin (JNJ-28431754) 100 mg, Canagliflozin (JNJ-28431754) 300 mg
- Where
- 305 sites in United States, Argentina and 23 more
- Volunteers
- 4,330 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes Mellitus (T2DM)
Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin
This clinical trial is studying whether combining two commonly used diabetes medications into a single pill works better than taking them separately for people with type 2 diabetes who are already on metformin.
- Trial name
- CONTROL (NCT07057479)
- Testing
- Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione, Control Group 1 Intervention - SGLT2 inhibitor monotherapy, Control Group 2 Intervention - Thiazolidinedione monotherapy
- Where
- Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Renal Insufficiency, Chronic
Bringing Knowledge About Chronic Kidney Disease in Brazil: Filling the Gap
This is a multicenter cross-sectional study will randomly screen kidney function in adult patients with known risk factors for chronic kidney disease (CKD) within the Brazilian general population.
- Trial name
- Filling gap (NCT07103629)
- Where
- Brazil
- Volunteers
- 8,428 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)
The purpose of this study was to evaluate the long-term safety and tolerability of ezetimibe 10 mg once daily co-administered with atorvastatin 10 to 80 mg daily for up to 12 consecutive months in participants with heterozygous…
- Trial name
- NCT03882996
- Testing
- Ezetimibe, Atorvastatin
- Volunteers
- 432 people
- Sponsor
- Organon and Co
Endometriosis
A Study of the Potential Risk Factors Linked to the Development of Severe Forms of Endometriosis
This study will aim to identify genetic, medical, dietary and environmental factors associated with the development of endometrioma and/or deep infiltrating endometriosis in order to move towards early diagnosis and…
- Trial name
- FEELING (NCT01351051)
- Where
- 7 sites in China, France and 1 more
- Volunteers
- 1,008 people
- Sponsor
- Ipsen
ICD, Cardiomyopathy Ischemic
Assessment of Risk Factors for Appropriate ICD (Implantable Cardioverter-defibrillator) Intervention in Patients With Ischemic Cardiomyopathy
Design: PARCADIA is a prospective non-randomized non-interventional multi-center clinical investigation in Europe. Patients with depressed LV (left ventricular) function assessed on local standards, of ischemic origin and on…
- Conditions
- ICD, Cardiomyopathy Ischemic, Primary Prevention
- Trial name
- PARCADIA (NCT04014946)
- Testing
- ICD implantation
- Volunteers
- 200 people
- Sponsor
- Biotronik SE & Co. KG
Renal Cell Carcinoma
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
The purpose of this study is to test the effectiveness and safety of nivolumab combined with ipilimumab compared to nivolumab monotherapy in participants with previously untreated kidney cancer that has spread.
- Trial name
- NCT03873402
- Testing
- Nivolumab, Ipilimumab
- Where
- 78 sites in United States, Argentina and 12 more
- Volunteers
- 437 people
- Sponsor
- Bristol-Myers Squibb
Obesity
Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)
The primary objective was to assess the effect of SR141716 on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with or without comorbidities.
- Trial name
- NCT00386061
- Testing
- rimonabant (SR141716)
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 1,507 people
- Sponsor
- Sanofi
Prematurity, Vascular Aging
Exclusive Human-milk in Preterm NEOnates and Early VASCular Aging Risk Factors (NEOVASC)
Early vascular aging has its origins in fetal and neonatal life. The NEOVASC clinical trial aims to determine the effects of an exclusive human milk diet in extremely preterm infants on long-term cardiovascular health.
- Trial name
- NEOVASC (NCT04413994)
- Testing
- Humavant
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Prolacta Bioscience
Cardiovascular Risk Factor, Cardiovascular Diseases
Utility of the SomaLogic Cardiovascular Disease (CVD) Secondary Risk Panel for Cardiovascular Risk
This is a prospective pilot study of participants who have stable coronary heart disease (CHD). Participants undergo risk stratification using the SomaLogic Cardiovascular Disease (CVD) Risk Panel blood test at baseline and again…
- Trial name
- NCT03599531
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- SomaLogic, Inc.